Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 18/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17940596 | 0.90 | ENPP2 (0.63) | ENPP2 | |
| SCHEMBL16614215 | 0.89 | ENPP2 (0.62) | ENPP2 | |
| SCHEMBL16614228 | 0.89 | ENPP2 (0.57) | ENPP2AKR1B1PTGDR2 | |
| SCHEMBL16600384 | 0.88 | ENPP2 (0.53) | ENPP2AKR1B1PTGDR2 | |
| SCHEMBL16600530 | 0.85 | ENPP2 (0.58) | ENPP2 | |
| SCHEMBL17943189 | 0.83 | ENPP2 (0.85) | ENPP2 | |
| SCHEMBL16600422 | 0.82 | ENPP2 (1.00) | ENPP2 | |
| SCHEMBL16600643 | 0.81 | ENPP2 (0.98) | ENPP2 | |
| SCHEMBL16751070 | 0.81 | ENPP2 (0.63) | ENPP2 | |
| SCHEMBL16751031 | 0.81 | ENPP2 (0.63) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-3049405-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | Pharmakea Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885AKR1B1 3956/4885PTGDR2 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.